[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ningbo Medical Center Lihuili Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":276},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,68,89,107,131,150,179,208,233,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636978","transcutaneous-electrical-acustimulation-tea-for-the-treatment-of-non-erosive-gastroesophageal-reflux-disease-nerd-100636978",false,"NCT07572708","Transcutaneous Electrical Acustimulation (TEA) for the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)","Transcutaneous Electrical Acustimulation (TEA) for the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD): A Multicenter, Randomized, Sham-Controlled Trial","Inclusion Criteria:\n\n* Age 18-75 years, irrespective of gender\n* Typical heartburn symptoms for at least 3 months\n* Heartburn on at least 2 days during the run-in diary period\n* Endoscopically confirmed NERD (no esophageal erosions, Los Angeles grade N or M) within 12 months\n* Willingness and ability to comply with all study procedures and to provide written informed consent\n\nExclusion Criteria:\n\n* Familiarity with acupuncture points and their functions (e.g., previous acupuncture experience or medical training)\n* Any esophageal structural or mucosal disease (e.g., Barrett's esophagus, erosive esophagitis LA grade A-D, eosinophilic esophagitis, esophageal stricture, varices, malignancy, or prior chemical\u002Fthermal\u002Fradiation injury)\n* Presence of gastric or duodenal ulcers\n* History of or suspected diagnosis of functional heartburn or functional dyspepsia by Rome IV criteria\n* Systemic diseases affecting gastrointestinal motility (e.g., systemic sclerosis, dermatomyositis, systemic lupus erythematosus, amyloidosis), uncontrolled diabetes mellitus (fasting glucose ≥11.1 mmol\u002FL or glycated hemoglobin ≥7.0%), severe cardiovascular disease, significant hepatic or renal dysfunction, or severe psychiatric disorders\n* Inability to discontinue prohibited medications (PPIs, P-CABs, H2RAs, prokinetics, or other GERD-directed therapies) except for protocol-defined rescue medication during the study\n* Implanted electronic devices (e.g., pacemaker, defibrillator) or other implants susceptible to electrical stimulation\n* Local skin disease or severe hypersensitivity at stimulation sites\n* Pregnancy, breastfeeding, or planned pregnancy during the study period\n* Participation in other interventional clinical trials within the past 3 months","ALL","18 Years","75 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter study aims to evaluate whether Transcutaneous Electrical Acustimulation (TEA) is effective in treating Non-Erosive Gastroesophageal Reflux Disease (NERD). NERD is a common condition where patients experience symptoms like heartburn and regurgitation, but no visible damage can be seen in the esophagus during an endoscopy. TEA is a non-invasive treatment that uses a small device to deliver mild electrical stimulation through the skin on specific acupoints. This study will compare the effects of real TEA treatment with a sham (inactive) control. Participants will be randomly assigned to one of two groups: active TEA treatment or sham stimulation. Neither the participants nor the researchers evaluating the outcomes will know which treatment is being given. The main outcome is the improvement of reflux symptoms after 4 weeks of treatment. The results of this study may provide a new non-drug option for patients suffering from NERD.",[27],"Non-erosive Reflux Disease (NERD)",[29,30,31,32],"NERD","Transcutaneous electrical Acustimulation","Neuromodulation","Multicenter","NOT_YET_RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":21},"2026-05-01",{"date":41,"type":21},"2028-03-31",{"name":43,"class":44},"Ningbo Medical Center Lihuili Hospital","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100634616","phase-2-liposomal-irinotecan-5-fluorouracilcalcium-folinate-oxaliplatin-and-adebrelimab-in-combination-with-radiotherapy-for-resectable-or-borderline-resectable-pancreatic-cancer-with-risk-factorsa-prospective-exploratory-study-100634616","NCT07542002","Liposomal Irinotecan, 5-fluorouracil\u002FCalcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study","Inclusion Criteria:\n\nPatients must meet the following criteria to be eligible for enrollment in this study:\n\n1. Age 18 to 75 years, regardless of gender;\n2. Histologically or cytologically confirmed pancreatic cancer (arising from the pancreatic ductal epithelium), as assessed by a multidisciplinary team (MDT), with clinical records indicating resectable or borderline resectable pancreatic cancer with high-risk factors. (According to the 2022 edition of the CSCO guidelines, borderline resectable pancreatic cancer is defined as: ① Tumor contact with the portal vein-superior mesenteric vein \\> 180°, or contact ≤180° combined with irregular venous contour or venous thrombosis, but with the possibility of complete resection and safe reconstruction; tumor contact with the inferior vena cava; ② (For pancreatic head\u002Funcinate process tumors) Tumor contact with the common hepatic artery, but without involvement of the celiac artery or the origin of the left or right hepatic arteries, with the possibility of complete resection and safe reconstruction; tumor contact with the superior mesenteric artery ≤180°; tumor contact with variant arteries (e.g., accessory right hepatic artery, replaced right hepatic artery, replaced common hepatic artery, etc.). (For pancreatic body\u002Ftail tumors) Tumor contact with the superior mesenteric artery ≤180°; tumor contact with the celiac artery ≤180°.) (According to the 2022 edition of the CSCO guidelines, high-risk factors are defined as \"very high CA19-9, large primary tumor, massive regional lymph node metastasis, significant weight loss, and severe pain.\" In this study, high-risk factors are defined as \"CA199 \\> 200 U\u002FmL, maximum tumor diameter \\> 2 cm, N1 or higher.\")\n3. Presence of at least one measurable lesion as a target lesion (according to RECIST v1.1 criteria);\n4. No prior anti-tumor treatment (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.) or investigational drug therapy;\n5. ECOG performance status: 0-1;\n6. Life expectancy of ≥ 3 months;\n7. Adequate function of major organs, defined as meeting the following criteria (without transfusion of blood products or administration of hematopoietic growth factors within 14 days prior to randomization):\n\n(1) Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL; platelets ≥ 80 × 10⁹\u002FL; hemoglobin ≥ 9 g\u002FdL; serum albumin ≥ 3 g\u002FdL; (2) Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (biliary drainage is permitted for biliary obstruction); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (for patients with liver metastasis, up to ≤ 5 × ULN is allowed); (3) Serum creatinine ≤ 1.5 × ULN, and creatinine clearance ≥ 60 mL\u002Fmin; (4) International Normalized Ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (patients on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, with INR within the therapeutic range of the anticoagulant, are eligible for screening); (5) Electrocardiogram: QTcF ≤ 450 ms (male), ≤ 470 ms (female); (6) Echocardiogram: Left ventricular ejection fraction (LVEF) ≥ 50%; 8. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to randomization and agree to use an appropriate method of contraception during the study and for 6 months after the end of treatment. For men, they should be surgically sterile or agree to use an appropriate method of contraception during the study and for 3 months after the end of treatment; 9. The subject voluntarily agrees to participate in this study and provides written informed consent.\n\nExclusion Criteria:\n\nPatients with any of the following criteria are ineligible for enrollment in this study:\n\n1. Pancreatic cancer originating from non-ductal epithelium of the pancreas, including pancreatic neuroendocrine tumors, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasms;\n2. Patients with known central nervous system metastasis;\n3. Severe gastrointestinal dysfunction (e.g., bleeding, obstruction; inflammation greater than Grade 2; diarrhea greater than Grade 1);\n4. Presence of third-space effusions (other than ascites) that cannot reach a stable state within 2 weeks prior to randomization (e.g., large pleural effusion that requires intervention after removal of drainage);\n5. Clinically symptomatic ascites requiring paracentesis or drainage, or patients who have undergone ascites drainage within the past 3 months (exceptions include those with minimal ascites detectable only on imaging and controllable without clinical symptoms);\n6. Known interstitial lung disease, excluding interstitial changes detected only on imaging;\n7. Known peripheral neuropathy (CTCAE ≥ Grade 3);\n8. Known deficiency or low activity of dihydropyrimidine dehydrogenase;\n9. Severe infection within 4 weeks prior to enrollment (CTCAE \\> Grade 2), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications; presence of signs and symptoms of infection within 2 weeks prior to randomization that require intravenous antibiotic therapy (excluding prophylactic use of antibiotics);\n10. Receipt of any of the following treatments:\n\n    * Use of strong inhibitors\u002Finducers of CYP3A4, CYP2C8, or strong inhibitors of UGT1A1 within 2 weeks prior to enrollment;\n    * Radiotherapy within 2 weeks prior to enrollment;\n    * Major surgery (e.g., thoracotomy, laparotomy) within 4 weeks prior to enrollment;\n    * Other investigational drug therapy within 4 weeks prior to enrollment, unless it was an observational (non-interventional) clinical study or follow-up of an interventional clinical study;\n11. Abnormal coagulation function, tendency to bleed, or ongoing thrombolytic or anticoagulant therapy. Low-dose aspirin (≤100 mg\u002Fday) and low molecular weight heparin (e.g., enoxaparin 40 mg\u002Fday or equivalent doses of other low molecular weight heparins) for prophylactic use are permitted;\n12. Uncontrolled cardiac clinical symptoms or diseases, such as: (1) NYHA Class 2 or higher heart failure; (2) unstable angina; (3) myocardial infarction within the past 6 months; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n13. History of malignancies other than pancreatic cancer within 5 years prior to enrollment, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;\n14. Known hypersensitivity to irinotecan liposome, other liposomal products, oxaliplatin, 5-FU, leucovorin calcium, adadelimab, or any component of the above products;\n15. Known acquired immunodeficiency syndrome (AIDS) or HIV-positive status, active syphilis infection;\n16. History of definite neurological or psychiatric disorders, including epilepsy or dementia;\n17. As judged by the investigator, the subject has other factors that may lead to forced discontinuation of the study, such as non-compliance with the protocol, concomitant treatment required for other severe diseases (including psychiatric diseases), clinically significant laboratory abnormalities, family or social factors that may affect the subject's safety or the collection of trial data, etc.",{"count":53,"type":21},37,[55],"PHASE2","Pancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis. In recent years, both the incidence and mortality rates of pancreatic cancer have shown a marked upward trend worldwide. Global cancer statistics from 2020 indicate that approximately 495,000 new cases of pancreatic cancer are diagnosed annually, with about 466,000 deaths attributed to this disease each year. Based on the anatomical relationship between the tumor and blood vessels, pancreatic cancer is classified into three types: resectable, borderline resectable, and unresectable. The onset of pancreatic cancer is often insidious, with approximately 80% of patients presenting with advanced disease at the time of initial diagnosis, thereby losing the opportunity for radical surgical resection. Only 15-20% of patients are eligible for radical surgery at the time of initial diagnosis. However, even after surgical resection, many patients still experience early recurrence, leading to a very poor prognosis. This highlights the significant limitations of relying solely on surgery for disease control.\n\nCurrently, there is no standard neoadjuvant treatment protocol for pancreatic cancer. Recent neoadjuvant clinical trials have primarily referenced chemotherapy regimens used for advanced pancreatic cancer, which may include chemotherapy and\u002For radiotherapy. Recommended chemotherapy regimens include the FOLFIRINOX regimen, gemcitabine plus nab-paclitaxel, gemcitabine plus cisplatin (for BRCA1\u002F2 mutations), and gemcitabine plus S-1. At the 2023 ASCO Annual Meeting, updated data from the NAPOLI-3 study showed that the NALIRIFOX regimen (irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin) achieved overall survival (OS) endpoints in first-line treatment of metastatic pancreatic cancer patients compared to the AG regimen, with clinical significance. Based on this study, the NCCN guidelines have included the NALIRIFOX regimen as a recommended first-line treatment for advanced pancreatic cancer. Given the therapeutic and safety advantages of irinotecan liposome over irinotecan in pancreatic cancer, this study aims to further explore the efficacy and safety of irinotecan liposome, 5-fluorouracil\u002Fleucovorin, oxaliplatin, and adabelimab combined with radiotherapy for resectable or borderline resectable pancreatic cancer with high-risk factors. The goal is to identify a more effective treatment option for patients with borderline resectable pancreatic cancer (BRPC) and resectable pancreatic cancer (RPC), thereby improving survival outcomes.\n\nThis study is a prospective, single-arm, exploratory trial designed to evaluate the efficacy and safety of irinotecan liposome, 5-fluorouracil\u002Fleucovorin, oxaliplatin, and adabelimab combined with radiotherapy for resectable or borderline resectable pancreatic cancer with high-risk factors, with a planned enrollment of 37 patients. After screening and meeting the inclusion and exclusion criteria, eligible patients will provide informed consent and undergo neoadjuvant treatment with irinotecan liposome, 5-fluorouracil\u002Fleucovorin, oxaliplatin, and adabelimab (with a 2-week cycle) for a total of four cycles of preoperative chemotherapy combined with immunotherapy, along with five sessions of short-course radiotherapy.",[58],"Pancreatic Cancer","RECRUITING","2026-04-14",{"date":62,"type":37},"2026-04-21",{"date":64,"type":37},"2025-03-25",{"date":66,"type":21},"2026-05-31",{"name":43,"class":44},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":45},"100621238","a-retrospective-study-of-safety-and-efficacy-of-locoregional-therapies-combined-with-anti-vegftkis-and-immune-checkpoint-inhibitors-for-all-comers-of-intention-to-treat-patients-with-unresectable-hepatocellular-carcinoma-100621238","NCT07368023","A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF\u002FTKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Aged 16 years or older.\n* Clinical and\u002For pathological diagnosis of hepatocellular carcinoma (HCC). China Liver Cancer (CNLC) stage I, II, or IIIA.\n* Assessed by a multidisciplinary team (MDT) as having initially unresectable HCC.\n\nExclusion Criteria:\n\n* Presence of extrahepatic metastasis.\n* Presence of Cheng's type IV portal vein tumor thrombus (PVTT).\n* Presence of Cheng's type II or III inferior vena cava tumor thrombus (IVCTT).","16 Years",{"count":76,"type":21},300,"OBSERVATIONAL","This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (ITT) patients who received multidisciplinary conversion therapy. This therapy combines locoregional treatments (LRT, such as TACE or radiotherapy) with systemic therapy (anti-VEGF\u002Ftyrosine kinase inhibitors and immune checkpoint inhibitors) with the goal of down-staging tumors to allow for subsequent curative resection.\n\nThe study plans to enroll 300 subjects. The exposure group will include approximately 100 patients with initially unresectable HCC who received the combined conversion therapy between January 2018 and December 2024. A control group of about 200 patients with initially resectable HCC who underwent direct radical surgery during the same period will be used for comparison. Data will be collected retrospectively from hospital electronic medical records and the HCC clinical database, with follow-up until December 2025.",[80,81],"Hepatocellular Carcinoma","Hepatocellular Carcinoma Non-resectable","2026-01-20",{"date":84,"type":37},"2026-01-26",{"date":86,"type":21},"2026-01-25",{"date":66,"type":21},{"name":43,"class":44},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100616840","a-retrospective-study-of-safety-and-efficacy-of-locoregional-therapies-combined-with-anti-vegftkis-and-immune-checkpoint-inhibitors-for-all-comers-of-intention-to-treat-patients-with-hepatocellular-carcinoma-beyond-ucsf-criteria-before-liver-transplantation-100616840","NCT07310836","A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF\u002FTKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation","Inclusion Criteria:\n\n* Age ≥16;\n* Clinical diagnosis of HCC;\n* CNLC Stage I-IIIA.\n\nExclusion Criteria:\n\n* Extrahepatic metastasis;\n* Type IV portal vein tumor thrombus.",{"count":76,"type":21},"This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for liver transplantation. The primary objective is to assess the outcomes of these \"intention-to-treat\" patients who received locoregional therapies (LRT, such as TACE or radiotherapy) in combination with systemic therapy (anti-VEGF\u002FTyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors) as a \"conversion therapy\" prior to potential transplantation. This approach is distinct from traditional bridging or down-staging therapies by incorporating more aggressive systemic regimens. The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients beyond UCSF criteria who received the combined conversion therapy between January 2020 and December 2024. A control group of about 200 patients who met the UCSF criteria and were directly listed for transplantation in the same period will be used for comparison. Data will be collected from medical records and the China Liver Transplant Registry (CLTR), with follow-up until December 2025.\n\nPrimary outcome measures include:\n\nObjective Response Rate (ORR) of conversion therapy per mRECIST. Rate of successful down-staging to meet UCSF criteria.\n\n1-, 2-, and 3-year overall survival (OS) rates of the intention-to-treat population.\n\nActual liver transplantation rate after successful conversion. Post-transplant 1-, 2-, and 3-year OS and recurrence-free survival (RFS) rates.\n\nSecondary outcomes involve:\n\nSafety profiles of both conversion therapy and subsequent transplantation. Analysis of factors influencing conversion success and treatment efficacy. Determination of an optimal washout period for Immune Checkpoint Inhibitors prior to transplantation.\n\nThe study seeks to provide high-level evidence for optimizing pre-transplant conversion strategies for advanced HCC patients currently outside standard transplant criteria.",[80,98],"Liver Transplantation","2025-12-16",{"date":101,"type":37},"2025-12-30",{"date":103,"type":21},"2025-12-20",{"date":105,"type":21},"2026-03-31",{"name":43,"class":44},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100613933","phase-4-clinical-application-research-of-combined-therapy-in-eras-for-accelerated-orthopedic-rehabilitation-100613933","NCT07273032","Clinical Application Research of Combined Therapy in ERAS for Accelerated Orthopedic Rehabilitation","Inclusion Criteria:\n\n(1) Patients with meniscus injury were conscious and aware of the content of this study. (2) Good compliance and cooperation with relevant drug treatments; (3) Possess good language communication skills.\n\nExclusion Criteria:\n\nPatients with severe obesity; (2) People with cognitive dysfunction (such as Alzheimer's disease); (3) Those with severe heart, liver or kidney insufficiency.","20 Years","65 Years",{"count":116,"type":21},120,[118],"PHASE4","The double-blind method is adopted.Case selection Patients who underwent meniscus repair surgery under knee arthroscopy at Li Huili Hospital Affiliated to Ningbo University, the 906th Hospital of the People's Liberation Army (Joint Logistic Support Force of the Chinese People's Liberation Army), and Yangming Hospital Affiliated to Ningbo University (Yuyao People's Hospital), with ages set at 20 to 65 years old, are planned to be included in a sample size of 120 cases based on previous research experience, divided into 4 groups. They were respectively: the blank control group, the Henggu Bone Injury Healing Agent intervention group, the lower limb rehabilitation training system intervention group, and the Henggu Bone injury Healing agent combined with the lower limb rehabilitation training system intervention group, with 30 cases in each group. Grouping was conducted using a double-blind method, with random grouping carried out by a third-party organization.\n\n1. Inclusion criteria: (1) The patient is conscious and aware of the content of this study; (2) Those with good compliance; (3) Possess good language communication skills.\n2. Exclusion criteria: (1) Severely obese patients; (2) People with cognitive dysfunction; (3) Those with relevant serious complications; (4) Those with severe heart, liver or kidney insufficiency.\n3. Exclusion criteria: Those who received intervention with other anti-inflammatory and analgesic drugs after the operation.\n\nCriteria for terminating the study: Postoperative complications such as joint infection and deep vein thrombosis of the lower extremities occur after the operation.\n\nBlank control group: No intervention measures Lower limb rehabilitation training system intervention group: Received rehabilitation system intervention after the operation Henggu Bone Injury Healing Agent Intervention Group: Take Henggu Bone Injury Healing Agent after the operation The combined intervention group: After the operation, they took Henggu bone injury Healing Agent and received rehabilitation system intervention The knee joint function and pain scores of each group, the implementation of the recovery plan, remote guidance of the rehabilitation system (applicable to the intervention group), and the duration of drug use: a total of 6 weeks of Henggu Bone Injury Healing Agent were evaluated at 1 day, 4 weeks, 3 months, and 6 months after the operation.",[121],"Meniscus Injury",[123],"Patients who have undergone meniscus repair surgery under knee arthroscopy","2025-12-08",{"date":126,"type":37},"2025-12-09",{"date":101,"type":21},{"date":129,"type":21},"2026-12-31",{"name":43,"class":44},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100577933","efficacy-of-individualized-aerobic-exercise-training-in-patients-with-inflammatory-bowel-disease-100577933","NCT06804733","Efficacy of Individualized Aerobic Exercise Training in Patients With Inflammatory Bowel Disease","Telemedicine-based Individualized Aerobic Exercise Training in Adults With Inactive or Mildly Active Inflammatory Bowel Disease: A Semi-crossover Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with CD or UC for more than 3 months.\n* Disease activity in remission or mildly active (CD: CDAI \\\u003C 220; UC: pMS \\\u003C 5).\n* Baseline physical activity intensity is low, measured by the IPAQ Chinese version short form, and without a habit of \"regular exercise\".\n* Agree to participate in the study and accept a 12-week individualized aerobic exercise training program.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or planning to become pregnant within the next 3 months.\n* Presence of physical movement disorders or other chronic diseases that limit physical activity.\n* Having an ileostomy.\n* History of anal or intestinal surgery within the past 3 months.",{"count":139,"type":21},28,[24],"The goal of this clinical trial is to learn if a 12-week individualized aerobic training program helps manage inactive or mildly active inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) in adult patients aged 18-65 years. It will also assess participant compliance and the safety of the training program. The main questions it aims to answer are:\n\n1. Does this aerobic training program improve the cardiopulmonary function of participants?\n2. Does this aerobic training program help control disease activity?\n3. Does this aerobic training program improve participants' quality of life?\n\nResearchers will divide participants into two groups. One group will participate in the training program directly. The other group will first undergo a 12-week control intervention (i.e., standard treatment) before proceeding to the training program.\n\nParticipants will:\n\n1. Take part in the individualized aerobic training program according to their baseline physical activity level for 12 weeks.\n2. Visit the clinic once every 4 weeks for check-ups and tests.\n3. Keep a diary of symptoms.",[143],"Inflammatory Bowel Disease (IBD)",{"date":99,"type":37},{"date":146,"type":37},"2025-05-01",{"date":148,"type":21},"2027-05-31",{"name":43,"class":44},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100591610","effect-of-preserving-the-left-colic-artery-on-proximal-bowel-perfusion-100591610","NCT06982664","Effect of Preserving the Left Colic Artery on Proximal Bowel Perfusion","Effect of Preserving the Left Colic Artery on Proximal Bowel and Anastomotic Blood Perfusion During Radical Resection for Rectal Cancer: A Randomized Controlled Trial Based on Laser Speckle Contrast Imaging","Inclusion Criteria:\n\n1. a confirmed diagnosis based on pathological reports;\n2. patients who had not received any prior treatment;\n\nExclusion Criteria:\n\n1. a history of previous abdominal surgery or neoadjuvant chemotherapy\u002Fradiation affecting bowel perfusion or anastomosis;\n2. patients requiring emergency surgery due to acute complications;\n3. intraoperative findings necessitating a shift to alternative procedures, such as local excision, abdominoperineal resection, Hartmann's operation, or intersphincteric resection.","80 Years",{"count":159,"type":21},143,[24],"Patients with rectal or rectosigmoid cancer undergoing radical resection will be randomly assigned to either high-tie (HT) or low-tie (LT) ligation of the Inferior Mesenteric Artery (IMA). Proximal bowel blood perfusion will be measured using Laser Speckle Contrast Imaging, and the perfusion characteristics will be compared between the two ligation groups.\n\nAdditionally, for participants randomized to the LT group, an embedded prospective cohort sub-study will be performed. This sub-study involves controlled, temporary intraoperative occlusion of the preserved Left Colic Artery (LCA). During this temporary occlusion, LSCI will be used to assess the resulting changes in colonic perfusion, specifically measuring outcomes like the ischemic demarcation line (LOD) retraction distance, to further investigate the functional contribution of the preserved LCA. The overall trial aims to determine the optimal IMA ligation strategy based on objective perfusion data and a deeper understanding of LCA's role.",[163,164,165],"Rectal Cancer Surgery","Perfusion Imaging","Anastomosis, Leaking",[167,168,169,170],"rectal caner","Perfusion","Anastomosis leakage","Laser Speckle Contrast Imaging","2025-05-13",{"date":173,"type":37},"2025-05-21",{"date":175,"type":21},"2025-06-01",{"date":177,"type":21},"2026-06-30",{"name":43,"class":44},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":77,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100569049","detection-of-sepsis-occurrence-by-using-blood-fluorescence-100569049","NCT06689189","Detection of Sepsis Occurrence by Using Blood Fluorescence","Metabolite Fluorescence Analysis in Critically Ill Patients' Blood and the Development of a Blood Fluorescence Analytical Platform","Inclusion Criteria:\n\n1. Healthy control group: Individuals who are physically healthy with no underlying diseases and have not been hospitalized within the past two years. Recruitment for healthy volunteers will be conducted through notices and online media.\n2. Sepsis Experimental Group: Patients with confirmed infections, having qSOFA ≥ 2 and SOFA ≥ 2, will be screened and confirmed by a physician to meet the inclusion criteria.\n3. Non-septic Severe Control Group: Patients with suspected or confirmed infections, having a SOFA score of 1, will be screened and confirmed by a physician to meet the inclusion criteria.\n\nExclusion Criteria: minors, pregnant, individuals with mental illnesses, and other vulnerable groups.",true,{"count":188,"type":21},800,"1 Month","This study adopted a case-control study method to explore a reagent-free, highly sensitive, and frequently screened blood fluorescence metabolite analyzer for sepsis, which can detect the emergence of inflammatory free radicals before organ damage and shorten the diagnosis time of sepsis.",[192,193],"Sepsis","Organ Damage",[192,195,196,197,198,199],"Organ damage","Blood metabolite fluorescence","Machine learning","Deep learning","Fluorescence spectrum analytical platform","2024-11-12",{"date":202,"type":37},"2024-11-14",{"date":204,"type":37},"2024-01-24",{"date":206,"type":21},"2027-10-01",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":45},"100563203","fruquintinib-combined-with-adebrelimab-and-high-and-low-dose-radiotherapy-in-the-treatment-of-second-line-and-above-failure-mss-metastatic-colorectal-cancer-100563203","NCT06613113","Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.","A Single-arm, Single-center Clinical Study of Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender not limited；\n2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1；\n3. Previously identified as MSS type mCRC；\n4. Metastatic colorectal cancer (mCRC) with disease progression after receiving standard second-line treatment according to Chinese Society of Clinical Oncology ( CSCO) guidelines；\n5. At least one measurable lesion (RECIST 1.1)；\n6. Be able to adhere to the protocol during the research period；\n7. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. For individuals with a history of uncontrolled epilepsy, central nervous system disorders, or mental disorders, the clinical severity of which may hinder the signing of informed consent forms or affect the patient's adherence to oral medication, as determined by the researcher；\n2. Accompanied by other malignant tumors that have not been cured；\n3. The baseline blood routine and biochemical indicators of the subject do not meet the following criteria: hemoglobin ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; Platelets ≥ 100 × 109\u002FL; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 times the normal upper limit; Alkaline phosphatase (ALP) ≤ 2.5 times the normal upper limit value; Serum total bilirubin\\\u003C1.5 times the normal upper limit value; Serum creatinine\\\u003C1 times the upper limit of normal; Serum albumin ≥ 30g\u002FL；\n4. Serious (i.e. active) heart disease in clinical practice, such as symptomatic coronary heart disease, congestive heart failure, or severe arrhythmia requiring medication intervention, or a history of myocardial infarction in the past 12 months；\n5. Irreversible coagulation dysfunction or concurrent active massive bleeding；\n6. Combination of active infections requiring antibiotic treatment；\n7. Individuals who are allergic to any research drug ingredients；\n8. Women with concurrent pregnancy or lactation；\n9. Organ transplantation requires immunosuppressive therapy and long-term hormone therapy；\n10. Patients with autoimmune diseases；\n11. There is a history of drug treatment in previous plans。",{"count":216,"type":21},30,[24],"The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer.\n\nThe main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer.\n\nParticipants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.",[220],"MSS Metastatic Colorectal Cancer",[220,222,223,224],"Fruquintinib","Adebrelimab","High and Low Dose Radiotherapy","2024-09-22",{"date":227,"type":37},"2024-09-25",{"date":229,"type":37},"2024-08-07",{"date":231,"type":21},"2027-07-31",{"name":43,"class":44},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":186,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":45},"100452397","fecal-microbiota-transplantation-for-liver-failure-100452397","NCT05170971","Fecal Microbiota Transplantation for Liver Failure","The Clinical Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Acute-on-chronic Liver Failure","Inclusion Criteria:\n\n* Patients willing to sign informed consent\n* Patients aged 18-65\n* According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol \u002F L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)\n\nExclusion Criteria:\n\n* Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc;\n* Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc\n* Patients with liver cancer, lung cancer, lymphoma and other malignant tumors\n* Patients taking anticoagulants, mental diseases and immune diseases for a long time\n* Pregnant or lactating women.",{"count":241,"type":21},60,[24],"To investigate the safety, adverse reactions and therapeutic effects of fecal microbiota transplantation on patients with liver failure;to investigate the effect of fecal microbiota transplantation on the intestinal microecology and \"gut-liver axis immune system\" of liver failure, and further optimization of fecal microbiota transplantation technology.",[245],"Liver Failure",[247,248,249],"fecal microbiota transplantation","gut-liver axis","liver failure","2024-03-08",{"date":252,"type":37},"2024-03-12",{"date":254,"type":37},"2021-05-01",{"date":129,"type":21},{"name":43,"class":44},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":45},"100530582","the-efficacy-and-safety-of-drug-loaded-microsphere-bronchial-artery-chemoembolization-deb-bace-combined-with-anlotinib-and-adebelimumab-in-the-third-line-treatment-of-advanced-nsclc-a-prospective-single-arm-single-center-exploratory-clinical-study-100530582","NCT06188650","The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study","Inclusion Criteria:\n\n1. Age\\>18 years old, gender unlimited;\n2. According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), NSCLC was diagnosed by pathological histology;\n3. TNM staging is III - IV;\n4. Failure of second-line treatment according to the CSCO guidelines;\n5. ECOG PS score ≤ 2 points;\n6. Estimated survival time\\>3 months;\n7. Sign informed consent form\n\nExclusion Criteria:\n\n1. Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient;\n2. Patients with other malignant tumors that have not been cured;\n3. White blood cells\\\u003C3 × 109\u002FL, absolute value of neutrophils\\\u003C1.5 × 109\u002FL, neutrophil\u002Flymphocyte ratio ≥ 3, platelet count\\\u003C50 × 109\u002FL, hemoglobin concentration\\\u003C90 g\u002FL;\n4. Liver and kidney dysfunction (creatinine\\>176.8) μ Mol\u002FL; Aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT)\\>twice the normal upper limit;\n5. Central squamous cell carcinoma with cavity features;\n6. Incorrectable coagulation dysfunction or concomitant active massive hemoptysis;\n7. Patients with concurrent active infections who require antibiotic treatment;\n8. Uncontrollable hypertension, diabetes, and cardiovascular diseases with obvious symptoms;\n9. Contrast agent allergy;\n10. Women with concurrent pregnancy or lactation",{"count":216,"type":21},[24],"The goal of this clinical trial is to learn about Drug loaded microspheres for bronchial artery chemoembolization (DEB-BACE) combined with anlotinib and adebelimumab in patients with advanced NSCLC after second-line treatment.\n\nThe main question it aims to answer is:\n\nThe efficacy and safety of Drug Loading Beads Bronchial Arterial Chemoembolization (DEB-BACE) combined with Anlotinib and Adebelimumab in the third line treatment of advanced NSCLC.\n\nParticipants will receive DEB-BACE treatment, rest for 1 week and then undergo 1 cycle of treatment with combination of Anlotinib and Adebelimumab. With a maximum of 4 DEB-BACE treatments depending on the therapeutic effect, followed by continued treatment with Anlotinib and Adebelimumab.",[267],"Non-Small Cell Lung Cancer","2023-12-18",{"date":270,"type":37},"2024-01-03",{"date":272,"type":37},"2023-12-09",{"date":274,"type":21},"2026-09-30",{"name":43,"class":44},""]